Mavorixafor

Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome.^[1] It is a CXC chemokine receptor 4 antagonist.^[1] It is taken by mouth.^[1] It was developed by X4 Pharmaceuticals.

Mavorixafor

Clinical data
Trade names	Xolremdi
Other names	X4P-001; AMD-070
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Mavorixafor
Routes of administration	By mouth
Drug class	CXCR4 antagonist
ATC code	L03AX24 (WHO)
Legal status
Legal status	US: ℞-only[1]
Identifiers
IUPAC name N′-(1H-Benzimidazol-2-ylmethyl)-N′-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
CAS Number	558447-26-0
PubChem CID	11256587
IUPHAR/BPS	8580
DrugBank	DB05501
ChemSpider	9431613
UNII	0G9LGB5O2W
KEGG	D11510
ChEBI	CHEBI:138865
ChEMBL	ChEMBL518924
CompTox Dashboard (EPA)	DTXSID60971247
Chemical and physical data
Formula	C21H27N5
Molar mass	349.482 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
InChI InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1 Key:WVLHHLRVNDMIAR-IBGZPJMESA-N

The most frequently reported adverse reactions include thrombocytopenia (low platelet counts), rash, rhinitis (stuffy nose), epistaxis (nosebleed), vomiting, and dizziness.^[2]

Mavorixafor was approved for medical use in the United States in April 2024.^[1][2][3][4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[5]

Medical uses

Mavorixafor is indicated in people twelve years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.^[1][2]

Adverse effects

Mavorixafor is expected to cause harm to the baby.^[1][2]

History

The effectiveness of mavorixafor was evaluated in a 52-week, randomized, double-blind, placebo-controlled trial that enrolled 31 adolescents and adults with WHIM syndrome (NCT03995108).^[2] Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study.^[2] Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections.^[2] The average length of time over 24 hours that counts were above these levels was significantly longer with mavorixafor compared to the placebo group (15.0 hours compared to 2.8 hours for absolute neutrophil counts; 15.8 hours compared to 4.6 hours for absolute lymphocyte counts).^[2]

Society and culture

Names

Mavorixafor is the international nonproprietary name.^[6]

Research

Mavorixafor is in clinical trials for melanoma^[7] and renal cell carcinoma.^[8]